Priorities in Cardiac Surgery for Rheumatic Heart Disease  by Finucane, Kirsten & Wilson, Nigel
REVIEW gREVIEWj
Priorities in Cardiac Surgery for Rheumatic Heart Disease
Kirsten Finucane, Nigel Wilson
Auckland, New ZealandABSTRACT
This review outlines a philosophy of surgical cardiac care for rheumatic heart disease, which has evolved over
the past 2 decades, in the young in the Oceania region. Topics covered include the optimal timing of surgery,
recommended strategies for mitral and aortic valve disease, and the importance of the team approach to these
patients. There is a global priority for more cardiac surgeons to become skilled in repair of the rheumatic
mitral valve. Surgeons operating on patients from remote regions with RHD are encouraged to audit
outcomes and help these communities develop their health services to optimize continued RHD care.N. Wilson receives salary
support from CureKidz,
New Zealand.
From Green Lane Paediat-
ric and Congenital
Cardiology Services,As has been highlighted in other reports in this issue of
Global Heart, 80% of the world’s countries still have rheu-
matic fever and its important long-term sequel, rheumatic
heart disease (RHD). Thosewith severe RHD that donot have
access to cardiac surgery will die. The mean age of death in
some regions of Africa is as young as 25 years [1] and for the
indigenous Aborigine population of Australia, 22 years [2].
The particular challenge for a cardiac surgeon dealing
with severe RHD is to repair as many valves as possible
rather than replace them. The populations that suffer from
rheumatic fever, and the affected families within those
ethnic populations, have the least resources, lowest levels
of education, and worst access to health care. There is good
evidence to demonstrate how poorly people in these cir-
cumstances do with mechanical valve insertion and anti-
coagulation [3]. Unfortunately, rheumatic disease damages
the valve leaﬂets and subchordal apparatus, making repair
difﬁcult in comparison to other mitral and aortic lesions.
The surgeon and the cardiology unit need a team approach
to achieve good outcomes. It is not just about what hap-
pens in the operating theater, but it also involves good
triage, timely intervention, echocardiographic detailed
assessment, outreach clinics, nursing input for family ed-
ucation, post-operative case audit, and more.
This review outlines some of the approaches we have
used in Starship Hospital Auckland for the New Zealand
and Paciﬁc Island pediatric rheumatic population over the
past 2 decades to improve the outcomes of these children
and teenagers.Starship Hospital, Auck-
land, New Zealand. Corre-
spondence: K. Finucane
(KirstenF@adhb.govt.nz).
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CC BY-NC-ND license.EVIDENCE FOR THE SURVIVAL VALUE OF MITRAL
VALVE REPAIR
Antunes [4] in 1990 in South Africa was among the ﬁrst to
publish the dangers of using mechanical or bioprosthetic
valves in themitral position in the rheumatic population, both
adult and pediatric. This included both mortality rate per
patient-year and themortality rate of reoperation (Table 1) [4].
In 1999, a similar message was reported from New
Zealand in a study of women of child-bearing age requiringGLOBAL HEART, VOL. 8, NO. 3, 2013
September 2013: 213-220valve surgery, the commonest indication being rheumatic.
The outcome for those who had mechanical valve re-
placements was signiﬁcantly worse than those with repairs
or bioprostheses, many of which were aortic homografts
(Fig. 1) [5]. Paciﬁc Islanders and the indigenous Maori
women with mechanical valves had over 6 to 8 times
higher mortality than other ethnic groups did (Table 2).
Our unit has recently reported a survival advantage
following mitral valve (MV) repair compared with mitral
valve replacement (MVR) for the young with RHD [6]. This
retrospective study of 81 patients showed that from the time
of patient discharge, the long-term durability of mitral repair
was equal to that of MVR. Despite the need for early reop-
eration in 11% who underwent repair, freedom from reop-
eration was equal in the 2 groups for the duration of the
follow-up. Analysis of those with MVR reveals that 50% of
the patients with MVR had a signiﬁcant hemorrhagic,
thrombotic, or embolic event within 11 years, and rates of
endocarditis were also high. There was 100% freedom from
embolic, thrombotic, or hemorrhagic events in those with
MV repairs in this and other studies in the young [7e10].
For adults, despite the absence of a randomized
comparison between the results of valve replacement and
repair, it is widely accepted that valve repair is the optimal
surgical treatment in patients with severe mitral regurgi-
tation (MR) [11e13]. Compared with valve replacement,
MV repair has a lower perioperative mortality, better
preservation of post-operative left ventricular function,
improved survival, and lower long-term morbidity [13]. In
adults who are in sinus rhythm, repair avoids the need for
anticoagulation and risks of thromboembolism with pros-
thetic valves, makes pregnancy safe, allows for continued
participation in contact sports such as rugby, and avoids
the sudden deterioration that can occur with bioprosthetic
valves in the mitral position.
These data challenge the assumption that if there is
funding for 1 operation only, it is best to replace a valve
rather than repair it. This needs to be conﬁrmed with more
studies speciﬁcally in these populations that are vulnerable
to medication shortages, lack of monitoring, endocarditis,213
TABLE 1. Incidence of late mortality
Total %/
Patient-Year
Valve-Related %/
Patient-Year Ratio* %
Bioprosthetic
MVR
7.4 4.2 56.8
Mechanical
MVR
5.7 2.5 43.1
Mitral valve
repair
2.6 1.0 38.5
MVR, mitral valve replacement.
*Valve-related/total.
Adapted, with permission, Antunes [4].
TABLE 2. Relative risk of death in women with bioprosthetic or
mechanical valves
RR (95% CI)
Mechanical valve 2.17 (0.78e5.88)
Age at valve replacement, yrs 1.00 (1.00e1.01)
Number of concurrent valves 0.86 (0.39e1.92)
Years of operation 1.04 (0.93e1.16)
Maori 8.45 (1.82e39.3)
Paciﬁc Islander 6.54 (1.16e36.7)
Pregnancy 0.38 (0.17e0.84)
Valve site* 0.50 (0.11e2.39)
*Aortic or tricuspid versus mitral.
Adapted, with permission, from North et al. [5].
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214and medically unsupervised pregnancies, usually in early
adulthood. Following cardiac surgery, the challenge is to
achieve good follow-up by optimizing outreach clinics,
rheumatic fever registries, and nursing networks and
linking with the local staff who deliver secondary
prophylaxis.MITRAL VALVE REGURGITATION
Indications for cardiac surgery
There are many published guidelines addressing in-
dications for cardiac surgery for adult patients [11,13,14]
that are largely based on symptoms and echocardio-
graphic assessment of left ventricular size and function
(Table 3). Cardiologists, physicians, and pediatricians
should use these guidelines to refer RHD cases in a timelyFIGURE 1. Long-term survival of women according to
type of valve replacement. Among 232 women, 35 had
>1 valve state included. Test of difference in survival
between 3 valve types: p ¼ 0.002. Test of difference
between mechanical and bioprosthetic valve types: p ¼
0.04. B, bioprosthetic; H, homograft; and M, mechanical.
Adapted, with permission, from North et al. [5].fashion for surgery whether or not the patient is in a high-
income or low-income country setting. Patients with
chronic RHD who develop cardiac failure and impaired
ventricular function may be too late for effective cardiac
surgery due to failure of the myocardium to recover normal
function. Physicians working in remote settings historically
refer the sickest patients, but it may be appropriate for the
cardiac unit to decline such patients when ventricular
function is irrevocably impaired. A decision to not offer
surgery may be more humane after assessment in the local
setting rather than after the patient has traveled to an
overseas cardiac unit.MITRAL VALVE REPAIR
This complex topic is beyond the scope of this review, but
we have included several tables and ﬁgures outlining theTABLE 3. Class I indications for mitral valve surgery in adults
1 MV surgery is recommended for the symptomatic
patient with acute severe MR. (Level of Evidence: B)
2 MV surgery is beneﬁcial for patients with chronic
severe MR and NYHA functional class II, III, or IV
symptoms in the absence of severe LV dysfunction
(severe LV dysfunction is deﬁned as ejection
fraction <0.30) and/or end-systolic dimension >55
mm. (Level of Evidence: B)
3 MV surgery is beneﬁcial for asymptomatic patients with
chronic severe MR and mild to moderate LV
dysfunction, ejection fraction 0.30 to 0.60, and/or
end-systolic dimension 40 mm. (Level of
Evidence: B)
4 MV repair is recommended over MV replacement in the
majority of patients with severe chronic MR who
require surgery, and patients should be referred to
surgical centers experienced in MV repair. (Level of
Evidence: C)
LV, left ventricular; MR, mitral regurgitation; MV, mitral valve; NYHA,
New York Heart Association.
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TABLE 5. Mitral repair: surgical tactics
Shorten primary chordae of anterior leaﬂet (different
degrees according to echocardiogram)
Peel thickened layers off posterior leaﬂet
Resect small triangle from posterior leaﬂet (tends to be
redundant when annuloplasty is done)
Divide or extend posterior chordae that are retracting
leaﬂet—usually intermediate, not primary
Insert complete annuloplasty ring to restore oval shape
Close scallops in anterior or posterior leaﬂets to correct
localized areas of prolapse
Add Gore-Tex chords, translocate chords, use partial rings in
young children (not so durable)
gREVIEWj
important pathologic features and the repair techniques in
current use (Tables 4 and 5, Fig. 2). Cardiac surgeons in
different countries describe variable patterns of rheumatic
involvement in their patients, and each surgeon needs to
adapt techniques for these regional variations of RHD. The
more cases seen, the more obvious these patterns become
and the more practiced the surgeon can become. It is
sensible, at least at ﬁrst, for a surgeon at each unit to
achieve expertise before training another, given the tech-
nical difﬁculty of achieving good durable repairs.
A successful repair strategy starts with an under-
standing of the patient’s status: acute or chronic; degree of
dilation of the left ventricle; body-mass index; and
involvement of valves other than mitral. Following that, the
echocardiograph needs to be reviewed with the cardiologist
and it would be even better if this were repeated by a
transesophageal study as the operation starts. The hallmark
of the competent heart surgeon is the aim to repair rheu-
matic MV and to create repairs with good durability.
The echocardiographic detail of the site and severity of
excessive leaﬂet motion (prolapse), valve deﬁciency,
chordal thickening, and retraction is better than the in-
formation gained by direct inspection. Detailed echocar-
diography demonstrated by the cardiologist enables the
strategy of repair to be planned in detail before the oper-
ation starts and saves cross-clamp time.
Each segment of anterior and posterior leaﬂet should
be analyzed for prolapse and retraction, with an estimate of
the misalignment of the leaﬂets (slight, moderate, severe).
This allows the surgeon to plan how much to shorten cords
by allowing for the fact that the annuloplasty will tend to
aggravate the prolapse of the anterior leaﬂet particularly, so
mild prolapse cannot be ignored. The pre-operative echo
gives a better assessment of the valve mechanics than direct
inspection does, so little time needs to be wasted on
examining the valve once the cross clamp is on.
Replacement is a faster, easier job than repair, and
there can be pressure placed on the surgeon to give up if
the rest of the operative team has not been prepared for the
longer cross-clamp time that repair entails. Surgeons
should make sure these cases are scheduled with time
available, including the potential for a second bypass run if
the ﬁrst echo off bypass shows that the valve needs more
work. In our series, a long cross-clamp time is not a risk
factor for mortality or prolonged intensive care stay.
Transesophageal echocardiography at the end of the
procedure is used to decide whether the repair is adequate,TABLE 4. Rheumatic mitral valve pathology
Softening of chordae, elongation, rupture
Prolapse of part or all of 1 or both leaﬂets (often opposite)
Dilation of annulus, loses oval shape
Leaﬂet thickening and ﬁbrosis causing restriction of motion
Long-term evolution toward stenosis in adulthood,
independent of penicillin
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of residual regurgitation and stenosis: the age of the pa-
tient; the expected lifestyle of the patient, including plan
for pregnancy; the realistic chance of good anticoagulation
control; and the surgeon’s knowledge as to whether there is
any further improvement that can be made. Mild-moderate
valve regurgitation is often moderate by the time the pa-
tient is discharged. We use the left atrial pressure, measure
the valve gradient and detail the anatomy of the residual
valve regurgitation by transesophageal echocardiography.
Technical considerations include: Are the chords over-
corrected? Does the annuloplasty ring need downsizing? Is
there still localized leaﬂet prolapse? The ﬁnal decision
whether to revise the repair, accept it, or replace the valve
is made jointly by the surgeons and cardiologists.
Analysis of our own data has demonstrated some pa-
tient features that are risk factors for failure of mitral repair.
Valves with mixed mitral stenosis and regurgitation (Fig. 3)
or calciﬁed valves in the older adult may also be difﬁcult toFIGURE 2. Chordal shortening technique using pledg-
eted 4-0 ti-cron mattress suture. The degree of short-
ening is honed by adjusting the distance from start of
suture to the base of the chord.
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FIGURE 3. Three-dimensional transesophageal echocar-
diographic appearance of a severely thickened, immo-
bile rheumatic mitral valve (“ﬁsh-mouth” appearance)
with mixed stenosis and regurgitation.
FIGURE 4. MV repair versus MV replacement survival.
For MV repair: For MV replacement:
By 4 years, survival is 95%. By 4 years, survival is 100%.
By 8 years, survival is 90%. By 8 years, survival is 76%.
By 12 years, survival is 90%. By 12 years, survival is 38%.
MV, mitral valve.
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216repair. Repair can look acceptable on the operating table,
but patients may return early with severe mitral stenosis.
Kaplan-Meier survival curves and reoperation curves are
shown for a personal series of 135 mitral rheumatic op-
erations from 1996 to 2010, and they show that repair can
be achieved in 90% of ﬁrst-comers (Figs. 4 and 5).
Multivariate analysis from our unit’s published retro-
spective series showed that a left ventricular end-systolic
dimension of Z-score greater than 5 was the most impor-
tant determinant for mortality [6]. The hazard for the
myocardium not to recover appears especially high for
those with combined mitral and aortic disease [15]. The
clinical implication of this data is that referring physicians
in remote regions need to refer early, rather than when the
children are severely symptomatic, often with very dilated
left ventricles. We have experience of children referred
with massively enlarged left ventricles, and surgery will not
improve their life expectancy.
The probability of a durable valve repair is of crucial
importance. Until recently, durability of adult rheumatic
mitral repairs were not as good as nonrheumatic mitral
repairs [16], but there are several contemporary series from
experienced repair centers with high mitral repair rates and
low operative mortality [8,17e22].FIGURE 5. MV repair versus MV replacement freedom
from reoperation.
For MV repair: For MV replacement:
By 4 years, probability is
84%.
By 4 years, probability is 91%.
By 8 years, probability is
80%.
By 8 years, probability is 57%.
By 12 years, probability is
61%.ALTERNATIVES TO MITRAL REPAIR— MITRAL
VALVE REPLACEMENT
As a junior surgeon, I once replaced a mitral bioprosthesis
in a 12-year-old in whom it had been inserted only 2 years
before. Figure 6 demonstrates how quickly it had calciﬁed
in this Polynesian boy. This case illustrates how mitral
bioprostheses in the young are hazardous with frequent
life-threatening early failures [4,6]. Their only place is in
carefully supervised women intending to have pregnancies
within the next few years to avoid a mechanical valve with
warfarin.A better alternative for the unrepairable mitral is the
On-X mechanical valve (On-X Life Technologies, Austin,GLOBAL HEART, VOL. 8, NO. 3, 2013
September 2013: 213-220
FIGURE 6. Calciﬁed mitral bioprosthesis (porcine stented
valve) inserted 24 months prior to removal.
TABLE 6. Pathology—aortic
gREVIEWjTexas), a new-generation bileaﬂet prosthetic valve with
design features that, compared with other mechanical
valves, help reduce the risk of thrombosis. After an initial
promising study from South Africa in patients who failed
to take adequate warfarin [3], there is now increasing ev-
idence of freedom from embolic or thrombotic events,
including a U.S. Food and Drug Administrationeapproved
study of large numbers of patients in the United States
(PROACT [Prospective Randomized On-X Anticoagulation
Clinical Trial]; U.S. registration NCT00291525) [23].
Although these are mostly nonrheumatic patients, the
study conﬁrms that in carefully audited populations,
bleeding is closely linked to warfarin target levels of in-
ternational normalized ratio. We need to study dose
warfarin regimens in mitral patients to reduce the bleeding
complication rates without increasing thrombotic valve
complications.
We have a dedicated international normalized ratio
program in our unit using nurse practitioners to manage
warfarin in the community [24]. Surgeons inserting these
valves have a responsibility to advocate for optimized
systems for management of anticoagulation that will ensure
patient safety. Otherwise, it is conceivable that a mechan-
ical valve operation will shorten, not lengthen the life of
some of these children and teenagers.Dilation of annulus
Softening of leaﬂets, lose elasticity
Cup shape becomes like a saucer
Free edge becomes longer than attached edge, so prolapse
occurs
Free edge retracts/rolls back leaving a triangle-shaped
deﬁcit centrally
Leaﬂets thicken, develop parallel ridges or folds
Dilation of annulusMITRAL STENOSIS
The treatment of choice of pure mitral stenosis is balloon
mitral valvuloplasty [11,13,14], which usually is as effec-
tive as surgery and the hospital stay is short. However, in
some regions of the world, closed surgical mitral valvot-
omy may be less expensive than transferring to a country
with a cardiac catheterization laboratory. Open surgical
mitral valvuloplasty allows surgical debridement of theGLOBAL HEART, VOL. 8, NO. 3, 2013
September 2013: 213-220valve and is more efﬁcacious than balloon mitral valvulo-
plasty when there is signiﬁcant calciﬁcation of the valve or
there is mixed mitral stenosis and regurgitation.
AORTIC VALVE SURGERY
Pathologic features and repair tactics for aortic rheumatic
disease are shown in Tables 6 and 7.
Rheumatic aortic regurgitation is common in our
mitral cohort, but it is often only mild and therefore left
alone. When there is moderate aortic regurgitation in
conjunction with severe MR, echocardiographic analyses
may show single leaﬂet prolapse, which is amenable to
repair. Single leaﬂet prolapse produces an eccentrically
directed jet on echo and can be corrected by shortening the
free edge of the affected leaﬂet and slightly reducing the
annulus using subcommisural annuloplasty sutures.
However, if the aortic jet is directly back through the left
ventricular outﬂow tract and all leaﬂets are at equal level,
then the mechanism is pure leaﬂet retraction and repair is
more difﬁcult unless leaﬂet tissue is added. Our unit has
not had a policy of adding tissue, as we have excellent
results from homograft aortic valve insertion [25] and
prefer to use that if the valve regurgitation is signiﬁcant
enough to warrant it (moderate to severe or severe aortic
regurgitation). The homografts provide 8 to 12 years of
anticoagulant-free childhood and seem to allow some
annular growth so that a reasonable-sized mechanical valve
can then be inserted in adulthood.
Alternatively, the On-X aortic valve is proving a du-
rable alternative, with the promise of potentially avoiding
warfarin in patients with good left ventricular function and
normal rhythm. A current On-X trial. PROACT, aims to
show that aspirin and clopidogrel are as safe as warfarin.
We have been wary of using the Ross procedure in rheu-
matic patients given the degree of aortic annular dilation
present and the difﬁculty of detecting whether the pul-
monary has been damaged by the disease process [26].
OPTIMIZING PRE-OPERATIVE CARDIAC CARE
In our unit, we spend a lot of time discussing individual
cases to optimize the timing of their operations. Acute
patients are admitted and settled with diuretics and urgent
operations are rare: only indicated if the patient is in217
TABLE 7. Aortic repair tactics
Subcommisural annuloplasty sutures
Shortening of free edge of prolapsing leaﬂet—resect or
plicate
Reduce size of noncoronary sinus
Peel ﬁbrous layers or ridges off very thick areas of leaﬂet—
allows leaﬂet to extend
Extend 1 or more leaﬂets with autologous or animal tissue
Check opening is adequate with calibrator
Subcommisural annuloplasty sutures
j gREVIEW
218pulmonary edema; does not settle with intravenous di-
uretics; and requires mechanical ventilation. Occasionally
they present as acute pneumonia and on a ventilator, when
the ﬂail leaﬂet and severe MR is diagnosed on echo [27]. If
this is the child’s ﬁrst episode of acute rheumatic fever, the
noncompliant left atrium cannot dilate and pulmonary
venous hypertension causes pulmonary edema, which
sometimes has a remarkably unilateral appearance on the
chest radiograph and is often misdiagnosed as pneumonia.
Mitral repair is achievable in most of these acute cases.
Left ventricular dimensions are followed closely as well
as the erythrocyte sedimentation rate, because some pa-
tients have such torrential MR, or mitral and aortic
regurgitation, that the dimensions steadily increase to a
level that requires early intervention. Data following up
some of our combined valve disease patients suggest that
the left ventricular dimensions do not return to the normal
range at 6 to 12 months after surgery in those with severe
pre-operative dilation [15].
Early surgery raises concerns: 1) that overall compli-
cation rates will be higher due to the presence of systemic
inﬂammation; and 2) that the durability of repair will be
affected due to the softness of the tissues that are being
sutured. The technique of repair needs to be adjusted to
allow for this softening and to allow for the remodeling
process as the disease settles, which may shrink leaﬂets and
shorten chordae. There is a balance between the need to
protect the ventricle and the need for stronger tissues on
which to operate. We often compromise and operate at 2
or 3 months into the course of the illness when the C-
reactive protein has normalized and the ESR is settling.DELIVERY OF CARE
There is a single pediatric cardiothoracic unit in New
Zealand, with its population of 4.5 million, delivering pe-
diatric and congenital cardiac care throughout the country.
We perform around 350 bypasses per year with a mortality
rate of 1.5% to 2.5% for the last decade. The service is
publicly funded and free to New Zealand citizens. We
accept children from Paciﬁc Island countries of our region
for assessment and operation who are able to get funding
from a variety of charitable sources, but we are careful to
triage these children so that costs of care do not exhaust thefunds. Up to 50% of our rheumatic patients operated on
each year are from overseas.
All members of our cardiology team are involved in
outreach clinics, both around New Zealand and in many of
the Paciﬁc nations. The number of clinics has increased
steadily, and these visits have also allowed links to develop
between local doctors and our service. In the 2 decades since
these links began, the triage of patients and their manage-
ment in the community has improved markedly. In recent
years, a 3-year follow-up project in New Zealand and the
Paciﬁc Island countries has allowed us to track patients after
surgery and collect data on their survival and outcomes [6].
This valuable feedback then assists us in future decision
making so that operations can be tailored to the population
we are serving.
One of our concerns is the increasing number of teams
visiting third-world countries to perform operations for a
short period and then leaving. In many countries, these
visits provide the only chance of surgery for children. They
also provide valuable experience for those performing the
operations and are a great team-building exercise. Some
simpler congenital repairs are suitable for that situation,
and we know the patients are likely to do well even if there
is no further medical follow-up. However, the difﬁculty of
achieving a rheumatic valve repair in the type of theater set
up for such a visit leads many surgeons to perform me-
chanical valve replacements. Unless there is an adequate
health structure developed and supported for those pa-
tients, they may not do well. It is the responsibility of the
operating surgeon and team to audit the outcomes of this
type of surgery rather than assuming the outcomes will be
similar to those in a ﬁrst-world situation. In our opinion,
most rheumatic valve repair surgery is complex and re-
quires machinery and skills not easily set up for a week in a
third-world country.
The most worthwhile effort, particularly in the poorest
countries, is probably not in replacing valves in sick chil-
dren but in the less glamorous development of rheumatic
disease registries, penicillin delivery, and cardiac care
clinics with links to more-developed services. This is
harder to sell to charities raising money, but surgeons
involved in overseas visits or operating on these patients
also advocate for continued development of medical car-
diac programs for RHD and prevention in those countries
they support. Some small countries may never have their
own surgical pediatric cardiac service, but the local doctors
and nurses can be educated and supported over a number
of years to a level that will vastly improve the long-term
outcomes for those with RHD.SUMMARY
The main global priority for rheumatic heart surgery is to
increase the number of surgeons able to perform durable
repairs on mitral and aortic valves and to resort less often to
the easier option of replacement. This can only be achieved
by a multifactorial approach that includes careful workup ofGLOBAL HEART, VOL. 8, NO. 3, 2013
September 2013: 213-220
TABLE 8. Gems or golden rules: Rheumatic heart surgery
1. Rheumatic patients are at high risk for complications
of anticoagulation. Mitral repair, even with some
residual MS or MR, has a signiﬁcant survival
advantage over replacement.
2. Mitral bioprostheses may calcify very rapidly
(and silently) in children and young adults.
3. Mitral repair is difﬁcult and demands time and
dedication, so concentrate the experience into the
hands of 1 surgeon if possible.
4. Exact echocardiogram details of each segment of a
valve allows accurate planning for the operation
and saves surgical time.
5. Using a complete mitral annuloplasty ring restores the
oval shape and makes the most of the leaﬂet area
available.
6. Achieving a durable repair in a valve during an acute
episode of rheumatic fever is difﬁcult. If possible,
an operation is best avoided until the ESR settles.
7. Encourage local pediatricians and hospital
cardiologists to communicate closely to optimize
timing of operation. Survival and repair durability
are best if surgery is not left until the left ventricle
is grossly dilated.
8. Get involved in obtaining follow-up data, especially on
patients from other countries, to learn what works
and what is needed for the setting to which the
patient will return.
ESR, erythrocyte sedimentation rate; MR, mitral regurgitation; MS,
mitral stenosis.
gREVIEWjpatients, high-quality echocardiography, referral to a unit
with a dedicated surgeon experienced in rheumatic repair,
time allowed by the operative team, and development of the
service in the local community to continue optimal medical
care. Above all, RHD is an area that requires very good
communication between the surgeon and the cardiologist,
sometimes under stressful circumstances (leaky repair!), but
with a great sense of achievement for the patient when a
damaged valve is salvaged.
Our Unit’s golden rules for rheumatic heart surgery are
listed in Tables 8.ACKNOWLEDGMENT
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